2016-06-17 08:30:01 CEST

2016-06-17 08:30:01 CEST


REGULATED INFORMATION

English Finnish
Biohit Oyj - Company Announcement

Biohit Oyj Stock Options I 2013 will be registered in the Finnish book-entry system


Biohit Oyj Stock Exchange Release June 17, 2016 at 09:30 am local time (EEST)

Biohit Oyj has decided to convert all outstanding Biohit Oyj I 2013A–E stock
options into Biohit Oyj I 2013 stock options. Additionally, the Board of
Directors of Biohit Oyj has decided to register the Stock Options I 2013 in the
Finnish book-entry system. Registration will not affect the terms of the Option
Scheme or share subscription periods. 

Currently a total of 132,940 pcs of Stock Options I 2013 have been used for
share subscription. At the time of the conversion, the number of outstanding I
2013 stock options amounts to 367,060 pcs out of which 127,060 pcs have been
vested and a further 90,000 granted but not vested. 

Each option entitles its holder to subscribe for one new B-share in the
Company. The share subscription price is currently 2.2766 euros.  As a result
of the exercise of the stock options I 2013, the number of the Company’s shares
may increase by a maximum of 367,060 new shares. 

Stock Options I 2013 will not be listed on the Nasdaq Helsinki. New shares
subscribed with options I 2013 will be listed on the main list of the Nasdaq
Helsinki together with the Company’s existing B shares after the new shares
have been registered. Shares will establish shareholders rights as of the date
of share registration. 

Evli Bank Plc acts as a subscription place for share subscription with
Company’s I 2013 options. 

The terms and conditions of Biohit Oyj Stock Option Plan I 2013 are available
on the company’s website www.biohithealthcare.com/investors 

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com